1. Home
  2. DNN vs MLYS Comparison

DNN vs MLYS Comparison

Compare DNN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Denison Mines Corp (Canada)

DNN

Denison Mines Corp (Canada)

HOLD

Current Price

$2.36

Market Cap

2.3B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$22.25

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNN
MLYS
Founded
1954
2019
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.9B
IPO Year
1998
2023

Fundamental Metrics

Financial Performance
Metric
DNN
MLYS
Price
$2.36
$22.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
10
Target Price
$4.64
★ $48.50
AVG Volume (30 Days)
★ 24.0M
1.3M
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 37.43
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$321.58
N/A
Revenue Next Year
$38.26
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.20
$21.46
52 Week High
$4.43
$47.65

Technical Indicators

Market Signals
Indicator
DNN
MLYS
Relative Strength Index (RSI) 29.84 30.81
Support Level N/A N/A
Resistance Level $3.43 $31.19
Average True Range (ATR) 0.12 1.30
MACD -0.02 -0.61
Stochastic Oscillator 1.60 7.59

Price Performance

Historical Comparison
DNN
MLYS

About DNN Denison Mines Corp (Canada)

Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: